Symposium — Wednesday, April 26, 2017 — 10:30 AM - 12:30 PM — , Room W192A
Translational Physiology Interest Group — Chair: Lisandra E. de Castro Brás — Co-Chair: Ganesh V. Halade
This section will address the use of metabolites and peptides as novel biomarkers of cardiovascular disease, as well as the use of these small biologically active molecules as signaling factors in disease therapeutics. Metabolomics and peptidomics are new approaches that aim to measure metabolite and peptide dynamics in an unbiased manner. These techniques have helped to uncover new markers of cardiovascular disease, as well as potential targets for diagnose, prevention, and treatment. The study of peptides and metabolites and their cause/effect in disease is relevant because both are downstream of the genome, and therefore changes lead to amplification of the signal. Moreover, both proteome and metabolome can be affected by external perturbations, such as age, co-morbidities, nutrition, and medication. Thus, the study of the proteome and metabolome can provide insightful data on how to best treat particular patients and develop personalized patient care.